These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cooperative relationship between pharmaceutical companies, academia, and media explains sharp decrease in frequency of pulmonary complications after bortezomib in Japan. Narimatsu H; Hori A; Matsumura T; Kodama Y; Takita M; Kishi Y; Hamaki T; Yuji K; Tanaka Y; Komatsu T; Kami M J Clin Oncol; 2008 Dec; 26(35):5820-3. PubMed ID: 19001340 [No Abstract] [Full Text] [Related]
3. Enhancing care and managing side effects in patients receiving bortezomib. Colson K Clin Adv Hematol Oncol; 2006 May; 4(5):6-7; discussion 8; suppl 13. PubMed ID: 16832860 [No Abstract] [Full Text] [Related]
4. Subcutaneous bortezomib: a step towards optimised drug use. Mateos MV Lancet Oncol; 2011 May; 12(5):410-1. PubMed ID: 21507716 [No Abstract] [Full Text] [Related]
5. Speedy approvals for new cancer treatments. FDA Consum; 2003; 37(4):36. PubMed ID: 12971348 [No Abstract] [Full Text] [Related]
6. Children are not large mice. Horton T; Hunger SP Eur J Haematol; 2013 Jun; 90(6):535. PubMed ID: 23534840 [No Abstract] [Full Text] [Related]
8. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Kane RC; Farrell AT; Sridhara R; Pazdur R Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588 [TBL] [Abstract][Full Text] [Related]
9. Hyperlipidemia in a myeloma patient after bortezomib treatment. Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499 [No Abstract] [Full Text] [Related]
12. Bortezomib-induced cutaneous lupus in a patient with myeloma. Heelan K; McKenna DB J Dermatol; 2013 Feb; 40(2):123-4. PubMed ID: 23078265 [No Abstract] [Full Text] [Related]
13. Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug. Duek A; Feldberg E; Haran M; Berrebi A Am J Hematol; 2007 Jun; 82(6):502-3. PubMed ID: 17301973 [No Abstract] [Full Text] [Related]
14. Management of novel therapeutics' side effects: a nurse-centric model. Davies MJ ONS Connect; 2007; 22(8 Suppl):25-6. PubMed ID: 17824551 [No Abstract] [Full Text] [Related]
15. Sweet-like lesions induced by bortezomib: a review of the literature and a report of 2 cases. Truchuelo M; Bagazgoitia L; Alcántara J; Velasco D; Carrillo R Actas Dermosifiliogr; 2012 Nov; 103(9):829-31. PubMed ID: 22652505 [No Abstract] [Full Text] [Related]